We rely on the expertise from Optum Rx and their clinicians and their ability to use data to really help us.
Wespath Benefits and Investment
Kelly Wittich
Related healthcare insights
Article
Discover what plan sponsors need to know to help remove or limit cost as a barrier to medication access.
Article
PBMs don’t cause high drug costs — they’re part of the solution. Our drug prices beat the “low cost” vendors.
E-book
Specialty drug spend is a “top threat” to employer-provided benefits. Discover sustainable savings with your existing Optum Rx plan.
E-book
Many patients combined with expensive drugs leads to top spending classes.
Article
After revolutionizing care for diabetes and weight loss, GLP-1 drugs are being eyed for more. Can we afford it?
Driving down overall costs
With such significant market power across the drug supply chain, pharmaceutical manufacturers have sole discretion over how they price their products. That’s why it’s so important that we serve as the counterweight — and we are. Through negotiations, we are lowering the cost of prescription drugs and improving health outcomes:
- For every $1 spent, pharmacy benefit managers reduce costs by $10.
- Over the next 10 years, PBMs will help prevent 1 billion medication errors.
- 9 in 10 employers are satisfied with their PBM.
- We pass through 98% of the negotiated discounts and pharmacy rates to clients.
Explore our solutions to lower drug costs
Weight Engage
Get the most from these pricey new obesity drugs by choosing the right coverage strategy and helping your members build lifelong habits.
Controlling specialty drug costs
The cost and complexity of specialty drugs requires a solution that provides care without compromise. The outcome is a better experience and lower costs.
- 2024 UnitedHealth Group Investor Conference.
- 2024 analysis.
- 2023 program results.
- 2024 program results.